Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.41
-0.19 (-2.21%)
Apr 29, 2026, 9:59 AM EDT - Market open

Immix Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Net Income
-29.44-21.61-15.43-8.23-24.38
Upgrade
Depreciation & Amortization
0.360.120.0100
Upgrade
Other Amortization
----0.06
Upgrade
Stock-Based Compensation
2.443.022.570.620.22
Upgrade
Other Operating Activities
--0.08-0.17-22.91
Upgrade
Change in Accounts Payable
1.034.42.431.13-0.11
Upgrade
Change in Income Taxes
2.06-0.97-0.89-0.240.1
Upgrade
Change in Other Net Operating Assets
-0.380.540.11-0.7-0.38
Upgrade
Operating Cash Flow
-23.93-14.6-11.37-7.41-1.59
Upgrade
Capital Expenditures
-0.73-1.18-0.05--0
Upgrade
Investment in Securities
-6.48----
Upgrade
Investing Cash Flow
-7.21-1.18-0.05--0
Upgrade
Long-Term Debt Issued
----0.2
Upgrade
Total Debt Issued
----0.2
Upgrade
Short-Term Debt Repaid
----0.05-
Upgrade
Total Debt Repaid
----0.05-
Upgrade
Net Debt Issued (Repaid)
----0.050.2
Upgrade
Issuance of Common Stock
107.5215.9515.522.9118.65
Upgrade
Repurchase of Common Stock
----0.1-
Upgrade
Other Financing Activities
-0.14--0.060.47-
Upgrade
Financing Cash Flow
107.3915.9515.463.2318.85
Upgrade
Foreign Exchange Rate Adjustments
0-00.03-0.03-0.01
Upgrade
Net Cash Flow
76.250.174.07-4.2117.25
Upgrade
Free Cash Flow
-24.66-15.77-11.42-7.41-1.59
Upgrade
Free Cash Flow Per Share
-0.75-0.56-0.66-0.53-0.43
Upgrade
Cash Interest Paid
---0.010
Upgrade
Levered Free Cash Flow
-13.61-7.55-5.94-4.31-2.1
Upgrade
Unlevered Free Cash Flow
-13.61-7.55-5.94-4.31-2.04
Upgrade
Change in Working Capital
2.73.971.650.2-0.39
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.